{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T05:44:54Z","timestamp":1767764694452,"version":"3.48.0"},"reference-count":86,"publisher":"MDPI AG","issue":"1","license":[{"start":{"date-parts":[[2026,1,5]],"date-time":"2026-01-05T00:00:00Z","timestamp":1767571200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100017728","name":"Fondazione Anna Maria Sechi per il Cuore","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100017728","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCDD"],"abstract":"<jats:p>Background: Restenosis after coronary stent implantation remains a major clinical challenge, especially in patients with diabetes, long lesions, or multiple stents. Standard therapy with aspirin and P2Y12 inhibitors does not reliably prevent this complication. Objectives: We reviewed experimental and clinical evidence on cilostazol, a selective phosphodiesterase-3 inhibitor, as a strategy to reduce restenosis after percutaneous coronary intervention (PCI). Methods: Preclinical and clinical studies were critically appraised, focusing on the effects of cilostazol on vascular smooth muscle and endothelial cells, platelet aggregation, lipid metabolism, and restenosis rates. Results: Experimental models show that cilostazol inhibits smooth muscle proliferation and intimal hyperplasia after arterial injury. Clinical trials demonstrate reduced restenosis after balloon angioplasty and stent implantation compared with aspirin, ticlopidine, or clopidogrel. Although approved by the FDA for intermittent claudication, cilostazol remains underused in the prevention of coronary restenosis. Conclusions: Current evidence supports cilostazol as an effective adjunctive therapy to reduce restenosis following PCI. Wider adoption and further large-scale trials are warranted to better define its role in contemporary interventional practice.<\/jats:p>","DOI":"10.3390\/jcdd13010031","type":"journal-article","created":{"date-parts":[[2026,1,5]],"date-time":"2026-01-05T16:07:07Z","timestamp":1767629227000},"page":"31","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["A Critical Review of the Molecular and Clinical Effects of Cilostazol After Percutaneous Coronary Intervention"],"prefix":"10.3390","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2046-9175","authenticated-orcid":false,"given":"Roberto","family":"Ferrari","sequence":"first","affiliation":[{"name":"European Heart for Children, Corso Ercole I\u00b0 D\u2019Este 32, 44121 Ferrara, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pasquale","family":"Perrone Filardi","sequence":"additional","affiliation":[{"name":"Department of Advanced Biomedical Sciences, Federico II University of Naples, Via Pansini, 5, 80131 Naples, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2026,1,5]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1016\/S0140-6736(15)61220-X","article-title":"Stable coronary artery disease: Revascularisation and invasive strategies","volume":"386","author":"Piccolo","year":"2015","journal-title":"Lancet"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1016\/j.jacc.2019.11.058","article-title":"Stent-related adverse events >1 year after percutaneous coronary intervention","volume":"75","author":"Madhavan","year":"2020","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1016\/S0002-9149(02)02869-2","article-title":"Meta-analysis of results from eight randomized, placebo-controlled trials on the effect of cilostazol on patients with intermittent claudication","volume":"90","author":"Thompson","year":"2002","journal-title":"Am. J. Cardiol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1248\/cpb.31.1151","article-title":"Studies on 2-oxoquinoline derivatives as blood platelet aggregation inhibitors: II. 6-[3-(1-cyclohexyl-5-tetrazolyl)propoxy]-1,2-dihydro-2-oxoquinoline and related compounds","volume":"31","author":"Nishi","year":"1983","journal-title":"Chem. Pharm. Bull."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1002\/jcph.1988","article-title":"Update on cilostazol: A critical review of its antithrombotic and cardiovascular actions and its clinical applications","volume":"62","author":"Manolis","year":"2022","journal-title":"J. Clin. Pharmacol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"2289","DOI":"10.2174\/1381612033453910","article-title":"Cilostazol as a unique antithrombotic agent","volume":"9","author":"Kambayashi","year":"2003","journal-title":"Curr. Pharm. Des."},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Park, Y., Kim, J.H., Kim, T.H., Koh, J.S., Hwang, S.J., Hwang, J.Y., and Jeong, Y.H. (2020). Adjunctive cilostazol to dual antiplatelet therapy to enhance mobilization of endothelial progenitor cells in patients with acute myocardial infarction: A randomized, placebo-controlled EPISODE trial. J. Clin. Med., 9.","DOI":"10.3390\/jcm9061678"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/S0002-9149(03)00458-2","article-title":"Effect of cilostazol on vasomotor reactivity in patients with vasospastic angina pectoris","volume":"92","author":"Watanabe","year":"2003","journal-title":"Am. J. Cardiol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/S0021-9150(98)00147-6","article-title":"Effects of a single local administration of cilostazol on neointimal formation in balloon-injured rat carotid artery","volume":"142","author":"Ishizaka","year":"1999","journal-title":"Atherosclerosis"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/S0002-9149(99)00368-9","article-title":"Comparison of cilostazol versus ticlopidine therapy after stent implantation","volume":"84","author":"Park","year":"1999","journal-title":"Am. J. Cardiol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1023\/B:CARD.0000033642.49162.04","article-title":"Comparison of cilostazol and ticlopidine for one-month effectiveness and safety after elective coronary stenting","volume":"18","author":"Hashiguchi","year":"2004","journal-title":"Cardiovasc. Drugs Ther."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1016\/j.amjcard.2004.12.012","article-title":"Comparison of cilostazol and clopidogrel after successful coronary stenting","volume":"95","author":"Lee","year":"2005","journal-title":"Am. J. Cardiol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1111\/j.1755-5922.2012.00312.x","article-title":"Efficacy of cilostazol on uncontrolled coronary vasospastic angina: A pilot study","volume":"31","author":"Yoo","year":"2013","journal-title":"Cardiovasc. Ther."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1345\/aph.1Q765","article-title":"Use of cilostazol in percutaneous coronary interventions","volume":"46","author":"Rogers","year":"2012","journal-title":"Ann. Pharmacother."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"53","DOI":"10.2165\/00003088-199937002-00006","article-title":"Effect of omeprazole on the metabolism of cilostazol","volume":"37","author":"Suri","year":"1999","journal-title":"Clin. Pharmacokinet."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.ijcard.2008.02.016","article-title":"The clopidogrel resistance can be attenuated with triple antiplatelet therapy in patients undergoing drug-eluting stents implantation","volume":"134","author":"Shim","year":"2009","journal-title":"Int. J. Cardiol."},{"key":"ref_17","first-page":"867964","article-title":"Clopidogrel-induced neutropenia after coronary stenting: Is cilostazol a good alternative?","volume":"2011","author":"Montalto","year":"2011","journal-title":"Int. J. Vasc. Med."},{"key":"ref_18","first-page":"387","article-title":"Effects of cilostazol on late lumen loss after Palmaz-Schatz stent implantation","volume":"44","author":"Yamasaki","year":"1998","journal-title":"Catheter. Cardiovasc. Diagn."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1016\/j.amjcard.2007.05.032","article-title":"Comparison of triple versus dual antiplatelet therapy after drug-eluting stent implantation (from the DECLARE-Long trial)","volume":"100","author":"Lee","year":"2007","journal-title":"Am. J. Cardiol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1016\/j.jacc.2007.11.049","article-title":"Drug-eluting stenting followed by cilostazol treatment reduces late restenosis in patients with diabetes mellitus: The DECLARE-DIABETES trial","volume":"51","author":"Lee","year":"2008","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1738","DOI":"10.1016\/j.amjcard.2013.08.008","article-title":"Comparison of dual versus triple antiplatelet therapy after drug-eluting stent according to stent length (from the pooled analysis of DECLARE trials)","volume":"112","author":"Lee","year":"2013","journal-title":"Am. J. Cardiol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1185\/03007995.2013.850067","article-title":"Long-term clinical efficacy and safety of adding cilostazol to dual antiplatelet therapy for patients undergoing PCI: A meta-analysis of randomized trials with adjusted indirect comparisons","volume":"30","author":"Chen","year":"2014","journal-title":"Curr. Med. Res. Opin."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.3892\/etm.2013.1238","article-title":"Triple versus dual antiplatelet therapy for coronary heart disease patients undergoing percutaneous coronary intervention: A meta-analysis","volume":"6","author":"Zhou","year":"2013","journal-title":"Exp. Ther. Med."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"3435","DOI":"10.2147\/DDDT.S119616","article-title":"The clinical outcomes of triple antiplatelet therapy versus dual antiplatelet therapy for high-risk patients after coronary stent implantation: A meta-analysis of 11 clinical trials and 9,553 patients","volume":"10","author":"Fan","year":"2016","journal-title":"Drug Des. Devel Ther."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"e000068","DOI":"10.1136\/openhrt-2014-000068","article-title":"Efficacy of cilostazol on platelet reactivity and cardiovascular outcomes in patients undergoing percutaneous coronary intervention: Insights from a meta-analysis of randomised trials","volume":"1","author":"Bangalore","year":"2014","journal-title":"Open Heart"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1161\/01.ATV.0000037100.44766.5B","article-title":"Inflammation and restenosis in the stent era","volume":"22","author":"Welt","year":"2002","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1660","DOI":"10.1016\/j.amjcard.2009.07.041","article-title":"Histopathology of clinical coronary restenosis in drug-eluting versus bare metal stents","volume":"104","author":"Chieffo","year":"2009","journal-title":"Am. J. Cardiol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1161\/CIRCULATIONAHA.113.001790","article-title":"Pathology of second-generation everolimus-eluting stents versus first-generation sirolimus- and paclitaxel-eluting stents in humans","volume":"129","author":"Otsuka","year":"2014","journal-title":"Circulation"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1016\/j.jacc.2020.08.002","article-title":"Trends and outcomes of restenosis after coronary stent implantation in the United States","volume":"76","author":"Moussa","year":"2020","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1111\/j.1527-3466.2001.tb00076.x","article-title":"Cilostazol (Pletal): A dual inhibitor of cyclic nucleotide phosphodiesterase type 3 and adenosine uptake","volume":"19","author":"Liu","year":"2001","journal-title":"Cardiovasc. Drug Rev."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1097\/00005344-200210000-00011","article-title":"New mechanism of action for cilostazol: Interplay between adenosine and cilostazol in inhibiting platelet activation","volume":"40","author":"Sun","year":"2002","journal-title":"J. Cardiovasc. Pharmacol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1161\/01.HYP.0000158263.64320.eb","article-title":"Cilostazol inhibits vascular smooth muscle cell growth by downregulation of the transcription factor E2F","volume":"45","author":"Kim","year":"2005","journal-title":"Hypertension"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1161\/01.HYP.35.1.237","article-title":"Cyclic AMP inhibited proliferation of human aortic vascular smooth muscle cells, accompanied by induction of p53 and p21","volume":"35","author":"Hayashi","year":"2000","journal-title":"Hypertension"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"2081","DOI":"10.1016\/S0024-3205(99)00157-5","article-title":"OPC-13013, a cyclic nucleotide phosphodiesterase type III inhibitor, inhibits cell proliferation and transdifferentiation of cultured rat hepatic stellate cells","volume":"64","author":"Shimizu","year":"1999","journal-title":"Life Sci."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1007\/s001250050787","article-title":"Role of hepatocyte growth factor in endothelial regulation: Prevention of high D-glucose-induced endothelial cell death by prostaglandins and phosphodiesterase type 3 inhibitor","volume":"40","author":"Morishita","year":"1997","journal-title":"Diabetologia"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1177\/0003319715606249","article-title":"Cilostazol enhances mobilization of circulating endothelial progenitor cells and improves endothelium-dependent function in patients at high risk of cardiovascular disease","volume":"67","author":"Chao","year":"2016","journal-title":"Angiology"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1097\/00004424-199509000-00004","article-title":"Pharmacologic treatment of intimal hyperplasia after metallic stent placement in the peripheral arteries: An experimental study","volume":"30","author":"Kubota","year":"1995","journal-title":"Investig. Radiol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1007\/s00415-012-6599-y","article-title":"Effects of cilostazol against the progression of carotid IMT in symptomatic ischemic stroke patients","volume":"260","author":"Heo","year":"2013","journal-title":"J. Neurol."},{"key":"ref_39","unstructured":"Otsuka America Pharmaceutical, Inc. (2007). Package Insert: Pletal (Cilostazol), Otsuka America Pharmaceutical."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1016\/0006-2952(94)90062-0","article-title":"Synergistic interactions between selective pharmacological inhibitors of phosphodiesterase isozyme families PDE III and PDE IV to attenuate proliferation of rat vascular smooth muscle cells","volume":"48","author":"Pan","year":"1994","journal-title":"Biochem. Pharmacol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/S0168-8227(00)00235-7","article-title":"Decrease in carotid intima media thickness after 1 year of cilostazol treatment in patients with type 2 diabetes mellitus","volume":"52","author":"Ahn","year":"2001","journal-title":"Diabetes Res. Clin. Pract."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1016\/S0002-8703(98)70327-8","article-title":"Impact of cilostazol on intimal proliferation after directional coronary atherectomy","volume":"135","author":"Tsuchikane","year":"1998","journal-title":"Am. Heart J."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1016\/j.jacc.2004.06.066","article-title":"Cilostazol inhibits leukocyte integrin Mac-1, leading to a potential reduction in restenosis after coronary stent implantation","volume":"44","author":"Inoue","year":"2004","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1097\/00005344-200009000-00011","article-title":"Inhibition of adenosine uptake and augmentation of ischemia-induced increase of interstitial adenosine by cilostazol, an agent to treat intermittent claudication","volume":"36","author":"Liu","year":"2000","journal-title":"J. Cardiovasc. Pharmacol."},{"key":"ref_45","first-page":"1157","article-title":"General pharmacological properties of cilostazol, a new antithrombotic drug. Part I: Effects on the central nervous system","volume":"35","author":"Shintani","year":"1985","journal-title":"Arzneimittelforschung"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1016\/0049-3848(90)90079-R","article-title":"Potentiation of anti-platelet aggregating activity of cilostazol with vascular endothelial cells","volume":"57","author":"Igawa","year":"1990","journal-title":"Thromb. Res."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"348","DOI":"10.5551\/jat.10.348","article-title":"Recovery of platelet function after withdrawal of cilostazol administered orally for a long period","volume":"10","author":"Iwamoto","year":"2003","journal-title":"J. Atheroscler. Thromb."},{"key":"ref_48","first-page":"1144","article-title":"Effect of cilostazol on platelet aggregation and experimental thrombosis","volume":"35","author":"Kimura","year":"1985","journal-title":"Arzneimittelforschung"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/S0049-3848(99)00109-7","article-title":"Effect of cilostazol, a phosphodiesterase III inhibitor, on experimental thrombosis in the porcine carotid artery","volume":"96","author":"Kohda","year":"1999","journal-title":"Thromb. Res."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1097\/00005344-198908000-00005","article-title":"Differential sensitivity to cardiotonic drugs of cyclic AMP phosphodiesterases isolated from canine ventricular and sinoatrial-enriched tissues","volume":"14","author":"Komas","year":"1989","journal-title":"J. Cardiovasc. Pharmacol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1055\/s-0037-1615217","article-title":"Effect of cilostazol on soluble adhesion molecules and platelet-derived microparticles in patients with diabetes","volume":"80","author":"Nomura","year":"1998","journal-title":"Thromb. Haemost."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1159\/000022512","article-title":"Comparison of the effects of acetylsalicylic acid, ticlopidine and cilostazol on primary hemostasis using a quantitative bleeding time test apparatus","volume":"29","author":"Tamai","year":"1999","journal-title":"Pathophysiol. Haemost. Thromb."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1016\/S0741-5214(03)01029-2","article-title":"Managing PAD with multiple platelet inhibitors: The effect of combination therapy on bleeding time","volume":"38","author":"Wilhite","year":"2003","journal-title":"J. Vasc. Surg."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1709","DOI":"10.1016\/S0024-3205(01)01258-9","article-title":"Endothelium-dependent relaxation by cilostazol, a phosphodiesterase III inhibitor, on rat thoracic aorta","volume":"69","author":"Nakamura","year":"2001","journal-title":"Life Sci."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1007\/s10238-015-0370-5","article-title":"Efficacy of cilostazol for the treatment of Raynaud\u2019s phenomenon in systemic sclerosis patients","volume":"16","author":"Negrini","year":"2016","journal-title":"Clin. Exp. Med."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"2979","DOI":"10.1016\/j.jstrokecerebrovasdis.2018.06.027","article-title":"Efficacy of cilostazol in prevention of delayed cerebral ischemia after aneurysmal subarachnoid hemorrhage: A meta-analysis","volume":"27","author":"Saber","year":"2018","journal-title":"J. Stroke Cerebrovasc. Dis."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/S0021-9150(99)00480-3","article-title":"Cilostazol, a selective type III phosphodiesterase inhibitor, decreases triglyceride and increases HDL cholesterol levels by increasing lipoprotein lipase activity in rats","volume":"152","author":"Tani","year":"2000","journal-title":"Atherosclerosis"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1517\/14656566.2011.557359","article-title":"Cilostazol and atherogenic dyslipidemia: A clinically relevant effect?","volume":"12","author":"Rizzo","year":"2011","journal-title":"Expert Opin. Pharmacother."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1053\/meta.2002.35191","article-title":"Cilostazol, a potent phosphodiesterase type III inhibitor, selectively increases antiatherogenic high-density lipoprotein subclass LpA-I and improves postprandial lipemia in patients with type 2 diabetes mellitus","volume":"51","author":"Ikewaki","year":"2002","journal-title":"Metabolism"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"152","DOI":"10.5551\/jat.25577","article-title":"A randomized comparison study assessing the impact of cilostazol on the heart rate and arrhythmias by 24-hour ambulatory Holter electrocardiographic monitoring after drug-eluting stent implantation for coronary artery disease","volume":"22","author":"Kwon","year":"2015","journal-title":"J. Atheroscler. Thromb."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1177\/147323000403200513","article-title":"Chronotropic effect of the antithrombotic agent cilostazol in a patient with sick sinus syndrome and syncope","volume":"32","author":"Moriya","year":"2004","journal-title":"J. Int. Med. Res."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"473","DOI":"10.31083\/j.rcm.2020.03.22","article-title":"Positive chronotropic effects of theophylline and cilostazol in patients with symptomatic sick sinus syndrome who have declined permanent pacing","volume":"21","author":"Jin","year":"2020","journal-title":"Rev. Cardiovasc. Med."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1007\/s12012-008-9019-x","article-title":"Antiplatelet agents sarpogrelate and cilostazol affect experimentally-induced ventricular arrhythmias and mortality","volume":"8","author":"Barta","year":"2008","journal-title":"Cardiovasc. Toxicol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1016\/j.jvs.2007.10.009","article-title":"Long-term safety of cilostazol in patients with peripheral artery disease: The CASTLE study (cilostazol: A study in long-term effects)","volume":"47","author":"Hiatt","year":"2008","journal-title":"J. Vasc. Surg."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.1016\/j.jacc.2005.07.048","article-title":"Triple versus dual antiplatelet therapy after coronary stenting: Impact on stent thrombosis","volume":"46","author":"Lee","year":"2005","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"34","DOI":"10.3349\/ymj.2013.54.1.34","article-title":"Adjunctive cilostazol versus high maintenance dose of clopidogrel in patients with hyporesponsiveness to chronic clopidogrel therapy","volume":"54","author":"Lee","year":"2013","journal-title":"Yonsei Med. J."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1097\/MCA.0000000000000026","article-title":"Effect of cilostazol addition or clopidogrel doubling on platelet function profiles in diabetic patients undergoing a percutaneous coronary intervention","volume":"24","author":"Ha","year":"2013","journal-title":"Coron. Artery Dis."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.1161\/CIRCULATIONAHA.117.030190","article-title":"Randomized comparisons of double-dose clopidogrel or adjunctive cilostazol versus standard dual antiplatelet in patients with high posttreatment platelet reactivity: Results of the CREATIVE Trial","volume":"137","author":"Tang","year":"2018","journal-title":"Circulation"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"127","DOI":"10.2174\/1570161116666180730100806","article-title":"Use of alternative antiplatelet agents for clopidogrel hypersensitivity","volume":"17","author":"Ather","year":"2019","journal-title":"Curr. Vasc. Pharmacol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1345\/aph.1G587","article-title":"Rash with both clopidogrel and ticlopidine in two patients following percutaneous coronary intervention with drug-eluting stents","volume":"40","author":"Makkar","year":"2006","journal-title":"Ann. Pharmacother."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"e1197\u2013201","DOI":"10.1097\/MJT.0000000000000238","article-title":"Clopidogrel-associated neutropenia: Case report and review of the literature","volume":"23","author":"Wu","year":"2016","journal-title":"Am. J. Ther."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1111\/j.1538-7836.2012.04788.x","article-title":"Pharmacodynamic effect of clopidogrel therapy and switching to cilostazol in patients with the CYP2C19 loss-of-function allele (ACCEL-SWITCH study)","volume":"10","author":"Jeong","year":"2012","journal-title":"J. Thromb. Haemost."},{"key":"ref_73","first-page":"321","article-title":"Antiplatelet effect of sequential administration of cilostazol in patients with acetylsalicylic acid resistance","volume":"32","author":"Cakmak","year":"2016","journal-title":"Acta Cardiol. Sin."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1067\/mhj.2001.111548","article-title":"Effects of cilostazol on late lumen loss and repeat revascularization after Palmaz-Schatz coronary stent implantation","volume":"141","author":"Kozuma","year":"2001","journal-title":"Am. Heart J."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1177\/1358836X0100600305","article-title":"Effects of cilostazol on resting ankle pressures and exercise-induced ischemia in patients with intermittent claudication","volume":"6","author":"Mohler","year":"2001","journal-title":"Vasc. Med."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1002\/clc.4960261004","article-title":"Rationale and design of the randomized, multicenter, Cilostazol for RESTenosis (CREST) trial","volume":"26","author":"Douglas","year":"2003","journal-title":"Clin. Cardiol."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1097\/01.fjc.0000167012.82930.8f","article-title":"RACTS: A prospective randomized antiplatelet trial of cilostazol versus ticlopidine in patients undergoing coronary stenting: Long-term clinical and angiographic outcome","volume":"46","author":"Ge","year":"2005","journal-title":"J. Cardiovasc. Pharmacol."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"e2062","DOI":"10.1097\/MD.0000000000002062","article-title":"It is not mandatory to use triple rather than dual anti-platelet therapy after a percutaneous coronary intervention with a second-generation drug-eluting stent","volume":"94","author":"Kim","year":"2015","journal-title":"Medicine"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.jacc.2010.08.631","article-title":"Multicenter randomized trial evaluating the efficacy of cilostazol on ischemic vascular complications after drug-eluting stent implantation: Results of the CILON-T trial","volume":"57","author":"Suh","year":"2011","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1007\/s40266-017-0463-9","article-title":"Outcome of triple antiplatelet therapy including cilostazol in elderly patients with ST-elevation myocardial infarction who underwent primary percutaneous coronary intervention: Results from the INTERSTELLAR registry","volume":"34","author":"Jang","year":"2017","journal-title":"Drugs Aging"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1159\/000338812","article-title":"Cilostazol-based triple antiplatelet therapy compared to dual antiplatelet therapy in patients with coronary stent implantation: A meta-analysis of 5,821 patients","volume":"122","author":"Geng","year":"2012","journal-title":"Cardiology"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1016\/j.amjcard.2012.01.349","article-title":"Meta-analysis of randomized controlled trials on effect of cilostazol on restenosis rates and outcomes after percutaneous coronary intervention","volume":"109","author":"Friedland","year":"2012","journal-title":"Am. J. Cardiol."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1002\/clc.22001","article-title":"The effectiveness and safety of triple-antiplatelet treatment based on cilostazol for patients receiving percutaneous coronary intervention: A meta-analysis","volume":"35","author":"Wang","year":"2012","journal-title":"Clin. Cardiol."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"2250","DOI":"10.1016\/j.ijcard.2012.06.010","article-title":"Cilostazol added to aspirin and clopidogrel reduces revascularization without increases in major adverse events in patients with drug-eluting stents: A meta-analysis of randomized controlled trials","volume":"167","author":"Sakurai","year":"2013","journal-title":"Int. J. Cardiol."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.3760\/cma.j.issn.0366-6999.20122839","article-title":"Efficacy and safety of triple-antiplatelet therapy after percutaneous coronary intervention: A meta-analysis","volume":"126","author":"Zhang","year":"2013","journal-title":"Chin. Med. J."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s40261-018-0711-8","article-title":"Effects of cilostazol-based triple antiplatelet therapy versus dual antiplatelet therapy after coronary drug-eluting stent implantation: An updated meta-analysis of randomized controlled trials","volume":"39","author":"Zhao","year":"2019","journal-title":"Clin. Drug Investig."}],"container-title":["Journal of Cardiovascular Development and Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2308-3425\/13\/1\/31\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T05:12:57Z","timestamp":1767762777000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2308-3425\/13\/1\/31"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,5]]},"references-count":86,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,1]]}},"alternative-id":["jcdd13010031"],"URL":"https:\/\/doi.org\/10.3390\/jcdd13010031","relation":{},"ISSN":["2308-3425"],"issn-type":[{"type":"electronic","value":"2308-3425"}],"subject":[],"published":{"date-parts":[[2026,1,5]]}}}